Pharmacogenomic (PGx) testing — analyzing how a patient’s genetic variants affect drug metabolism — has moved from research setting to retail and clinical pharmacy fairly quickly. The regulatory question hasn’t caught up as cleanly. This is a look at where pharmacist authority currently sits, state by state and role by role — not guidance on how to order, interpret, or act on a specific test.
Three distinct roles, three distinct authority questions
PGx testing involves several separate functions, and state scope-of-practice rules don’t always treat them the same way:
1. Facilitating or administering the test itself — collecting a buccal swab or saliva sample for a send-out lab test. This is the function most states treat most permissively, since it resembles other specimen-collection activities pharmacists already perform under point-of-care testing authority.
2. Ordering the test — determining that a PGx panel is clinically appropriate and initiating it, sometimes under a standing order, sometimes under a collaborative practice agreement (CPA), and in a smaller number of states under independent pharmacist ordering authority.
3. Interpreting results and making therapy recommendations — translating genotype data into an actionable recommendation (e.g., flagging a gene-drug interaction). This is where state authority is most inconsistent and most contested, because it overlaps with what many states consider diagnostic or prescriptive activity reserved for other license types unless specifically authorized.
How state frameworks tend to authorize this work
Most states that have addressed PGx testing at all do so through existing frameworks rather than PGx-specific statutes:
- Collaborative practice agreements are the most common vehicle. A CPA between a pharmacist and a supervising physician can explicitly authorize ordering and acting on PGx results within defined parameters, even where general pharmacist scope wouldn’t otherwise cover it. This mirrors how CPAs are used for other advanced services — see our overview of clinical pharmacist prescribing authority.
- CLIA-waived test authority governs the mechanics of point-of-care testing but doesn’t itself resolve whether a pharmacist can act on genetic results — most PGx panels are send-out lab tests rather than CLIA-waived point-of-care tests, so this framework applies to a minority of PGx workflows. Our point-of-care testing pharmacist authority piece covers how CLIA waivers work generally.
- Board-issued guidance documents — a handful of state boards have issued advisory opinions specifically addressing pharmacist involvement in pharmacogenomics, generally permitting facilitation and result communication but stopping short of authorizing independent clinical interpretation outside a CPA.
- Silence — most states haven’t addressed PGx testing directly at all, which means pharmacist authority defaults to how broadly (or narrowly) that state’s general scope-of-practice and CPA statutes are written.
Why “can a pharmacist do PGx testing” doesn’t have one answer
Ask that question and the honest answer is: it depends on which function, which state, which practice setting, and whether a CPA or standing order is in place. A pharmacist in a state with broad CPA statutes and an established physician partnership may have substantially more latitude than a pharmacist in a state with no PGx-specific guidance and a narrower default scope of practice — even though both are licensed under similar-sounding “pharmacist scope of practice” language.
Practice setting matters too. Health-system and specialty pharmacists working within an institution often operate under credentialing and privileging structures that grant broader PGx involvement than what a community pharmacist’s default state license would permit on its own. That distinction is similar to how test-and-treat authority plays out differently in institutional versus community settings.
The interpretation question is where most of the regulatory uncertainty sits
Because PGx results can look like a diagnostic output — flagging a genetic variant associated with altered drug response — some state boards and other regulators treat unsupervised interpretation as bordering on the practice of medicine or clinical laboratory science, not pharmacy. This is an unsettled area nationally, and how it’s treated can shift as new board guidance or legislation is issued. It is not something to infer from general scope-of-practice language without checking whether your state board has spoken on it directly.
What this means for pharmacists exploring PGx services
If you’re considering adding PGx-related services to your practice, the questions worth answering before anything else are regulatory, not clinical: does your state’s CPA statute (or a specific PGx guidance document) cover the functions you intend to perform, does your practice setting’s credentialing structure grant additional authority beyond the default state license, and has your state board issued anything specific to pharmacogenomics that would apply. None of this is a substitute for reading your state’s actual statutes and any board guidance, and it isn’t a substitute for your own institution’s or employer’s compliance review either.
Because this area moves quickly and unevenly across states, confirm current requirements directly with your state board of pharmacy before relying on any particular scope interpretation, and consult institutional policy and pharmacy law counsel for anything involving actual test ordering or interpretation.
RxByState tracks scope-of-practice and CPA regulatory developments — including emerging areas like pharmacogenomics — across all 50 states. See what’s tracked for your state →